Skip to main content
Werewolf Therapeutics, Inc. logo

Werewolf Therapeutics, Inc. — Investor Relations & Filings

Ticker · HOWL ISIN · US95075A1079 US Manufacturing
Open in API
Filings indexed 367 across all filing types
Latest filing 2024-02-09 Capital/Financing Update
Country US United States of America
Listing US HOWL

About Werewolf Therapeutics, Inc.

https://werewolftx.com/

Werewolf Therapeutics, Inc. is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company utilizes its proprietary PREDATOR® protein engineering platform to create a novel class of conditionally activated proinflammatory immune modulators, known as INDUKINE™ and INDUCER™ molecules. These therapies are designed to be delivered systemically in an inactive state and become selectively activated within the tumor microenvironment. This approach aims to generate a potent, localized anti-tumor immune response while minimizing the systemic side effects associated with conventional immunotherapies. The company's pipeline includes clinical-stage candidates such as WTX-124 and WTX-330.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a common stock offering. It details terms of a stock sale agreement, sales agent compensation, risk factors, use of proceeds, and other offering-related information. It is not a financial report, earnings release, or management discussion. It is a capital markets document focused on fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is a full prospectus supplement, not just an announcement or a brief notice.
2024-02-09 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated January 8, 2024, by Werewolf Therapeutics, Inc. It includes a business update press release and an updated corporate presentation. The text explicitly states that the press release and presentation are furnished as exhibits and incorporated by reference. The document does not contain detailed financial statements or substantive financial data itself but rather references external materials. The presence of an investor presentation as an exhibit and the nature of the update suggest this is primarily an investor presentation disclosure within a regulatory filing. Given the document length is under 5,000 characters and it mainly announces the availability of a presentation and press release, the best classification is Investor Presentation (IP).
2024-01-08 English
4
Director's Dealing
2024-01-05 English
3
Director's Dealing
2024-01-05 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 4, 2024, by Werewolf Therapeutics, Inc. The content focuses on the appointment of a new director, Michael B. Atkins, M.D., to the Board of Directors, including details about his background, committee membership, compensation, and indemnification agreement. There is no financial data, earnings information, or report publication mentioned. The primary subject is a change in the company's board of directors. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). Therefore, the correct classification is MANG with high confidence.
2024-01-04 English
4
Director's Dealing
2024-01-04 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.